Guidelines for the management of symptomatic breast disease

European Journal of Surgical Oncology

Volumn 31, Issue SUPPL., 2005, Pages

[No Author Info available]

Author keywords

Breast cancer; Breast disease; Guidelines

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADVANCED CANCER; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; BREAST DISEASE; BREAST RECONSTRUCTION; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CONTINUING EDUCATION; DOCTOR PATIENT RELATION; ECHOMAMMOGRAPHY; FAMILY HISTORY; FOLLOW UP; GENETIC PREDISPOSITION; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HIGH RISK PATIENT; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; INFORMATION PROCESSING; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; MEDICAL INFORMATICS; MEDICAL RECORD; MEDICAL SPECIALIST; MEDICAL STAFF; MULTIMODALITY CANCER THERAPY; ONCOGENE; OUTCOMES RESEARCH; PALLIATIVE THERAPY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUALITY CONTROL; REVIEW; STAFF TRAINING; SURGEON; SURGICAL ANATOMY; SYMPTOMATOLOGY; TUMOR SUPPRESSOR GENE; WORKLOAD;

EID: 17744372269     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.02.006     Document Type: Article

References (102)

1. Quality assurance guidelines for surgeons in breast cancer screening. NHS BSP; 1992, Publication No 20.
2. Breast Surgeons Group of BASO Guidelines for surgeons in the management of symptomatic breast disease in the UK Eur J Surg Oncol 21 Suppl A 1995 1-13
3. The BASO Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision). Eur J Surg Oncol 1998 24 464-76
4. A policy framework for commissioning cancer services: A report by the expert advisory group on cancer to the Chief Medical Officers of England and Wales. London: HMSO 1995
5. The NHS cancer plan - a plan for investment, a plan for reform. London: Department of Health 2000
6. NICE Improving outcomes in breast cancer - manual update 2002 National Institute for Clinical Excellence London
7. R. Sainsbury B. Haward L. Rider C. Johnston C. Round Influence of clinician workload and patterns of treatment on survival from breast cancer Lancet 345 1995 1265-1270
8. B.E. Hillner T.J. Smith C.E. Desch Hospital and physician volume or specialization and outcomes in cancer treatment: Importance in quality of cancer care J Clin Oncol 18 2000 2327-2340
9. C.R. Gillis D.J. Hole Survival outcome of care by specialist surgeons in breast cancer: A study of 3786 patients in the west of Scotland BMJ 312 1996 145-148
10. Quality assurance guidelines for nurses in breast cancer screening (revised). Sheffield: NHS Breast Screening Programme; 2002.
11. D.C. Jenner A. Middleton W.M. Webb R. Oommen T. Bates In-hospital delay in the diagnosis of breast cancer Br J Surg 87 2000 914-919
12. C.D. Collins Model workload agreement for DGH general surgeon: discussion paper Ann R Coll Surg Engl 72 Suppl 4 1990 48-50
13. Management in health care: The role of doctors. London: General Medical Council 1999
14. Good surgical practice. London: Royal College of Surgeons of England; 2000
15. Good medical practice. London: General Medical Council 2001
16. Quality assurance guidelines for radiographers (revised). Sheffield: NHS Breast Screening Programme Radiographers Quality Assurance Co-ordination Committee; 2000
17. Quality assurance guidelines for medical physics services in mammography in the NHSBSP. Sheffield: NHS Breast Screening Programme; 1995.
18. Radiographic quality control manual for mammography. Sheffield: NHS Breast Screening Programme 1993
19. Commissioning and routine testing of mammography X-ray systems. Sheffield: NHS Breast Screening Programme; 1994.
20. Quality assurance guidelines for radiologists. Sheffield: NHS Breast Screening Programme Radiologists Quality Assurance Committee; 1997.
21. Guidance on screening and symptomatic imaging. 2nd ed. London: The Royal College of Radiologists; 2003
22. N.A. Roche R.M. Given-Wilson V.A. Thomas N.P.M. Sacks Assessment of a scoring system for breast imaging Br J Surg 85 1998 669-672
23. Guidelines for breast pathology services. 2nd ed. NHSBSP Publication No. 2. Sheffield, UK: NHS Cancer Screening Programme; 1997.
24. Pathologists TRCo. Medical and Scientific Staffing of National Health Service Pathology Departments; 1999. p. 18-21.
25. Guidelines for non-operative diagnostic procedures in reporting in breast cancer screening. Sheffield, UK: National Cancer Screening Programme-non-operative diagnosis subgroup of the National Co-ordinating Group for Breast Screening Pathology; 2001.
26. Pathology reporting in breast cancer screening. 2nd ed. NHSBSP Publication No. 3. Sheffield, UK: NHS Cancer Screening Programme; 1997
27. J. Austoker R. Mansel M. Baum R. Sainsbury R. Hobbs Guidelines for referral of patients with breast problems 2nd ed 1999 NHS Breast Screening Programme Sheffield
28. Helath Circular HC 98/242
29. R. Given-Wilson G. Layer M. Warren J.-C. Gazet False negative mammography; causes and consequences The Breast 6 1997 361-366
30. A.B. Miller T. To C.J. Baines C. Wall The Canadian national breast screening study-1: Breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years Ann Intern Med 137 2002 305-312
31. M.A. Richards A.M. Westcombe S.B. Love P. Littlejohns A.J. Ramirez Influence of delay on survival in patients with breast cancer: A systematic review Lancet 353 1999 1119-1126
32. R. Sainsbury C. Johnston B. Haward Effect on survival of delays in referral of patients with breast-cancer symptoms: A retrospective analysis Lancet 353 1999 1132-1135
33. J. Todd C. Dowle M.R. Williams C.W. Elston I.O. Ellis C.P. Hinton et al. Confirmation of a prognostic index in primary breast cancer Br J Cancer 56 1987 489-492
34. B. Fisher S. Anderson J. Bryant R. Margolese M. Deutsch E.R. Fisher et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer N Engl J Med 347 2002 1233-1241
35. U. Veronesi R. Saccozzi M. Del Vecchio A. Banfi C. Clemente M. De Lena Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast N Engl J Med 305 1981 6-11
36. J.A. van Dongen H. Bartelink I.S. Fentiman T. Lerut F. Mignolet G. Olthuis et al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer Eur J Cancer 1992 801-805
37. R. Arriagada M.G. Le F. Rochard G. Contesso for the Insitut Gustave-Roussy Breast Cancer Group Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up J Clin Oncol 14 1996 1558
38. A.P. Forrest D. Everington C.C. McDonald R.J. Steele U. Chetty H.J. Stewart The Edinburgh randomized trial of axillary sampling or clearance after mastectomy Br J Surg 82 1995 1504-1508
39. B. Fowble L.J. Solin D.J. Schultz R.L. Goodman Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer Int J Radiat Oncol Biol Phys 17 1989 703-710
40. B.M. Siegel K.A. Mayzel S.M. Love Level I and II axillary dissection in the treatment of early-stage breast cancer. An analysis of 259 consecutive patients Arch Surg 125 1990 1144-1147
41. K.J. Halverson M.E. Taylor C.A. Perez D.M. Garcia R. Myerson G. Philpott et al. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer Int J Radiat Oncol Biol Phys 26 1993 593-599 [see comments]
42. U. Chetty W. Jack R.J. Prescott C. Tyler A. Rodger Management of the axilla in operable breast cancer treated by breast conservation: A randomized clinical trial Br J Surg 87 2000 163-169
43. A.E. Guiliano D.M. Kirgan J.M. Guenther D.L. Morton Lymphatic mapping and sentinel lymphadenectomy for breast cancer Ann Surg 220 3 1994 391-398 [discussion 398-401, see comments]
44. D. Krag D. Weaver T. Ashikaga F. Moffat V.S. Klingberg C. Shriver et al. The sentinel node in breast cancer-a multicenter validation study N Engl J Med 339 14 1998 941-946 [see comments]
45. U. Veronesi G. Paganelli G. Viale V. Galimberti A. Luini S. Zurrida et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series J Natl Cancer Inst 91 4 1999 368-373 [see comments]
46. R. Mansel A. Goyal L. Fallowfield R. Newcombe on behalf of the ALMANAC Trialists' Group Sentinel node biopsy versus standard axillary treatment: Results of the randomised multicenter UK ALMANAC trial Breast Cancer Res Treat 88 Suppl 1 2004 S13
47. T. Julian D. Krag A. Brown S. Anderson S. Harlow T. Ashikaga et al. Preliminary technical results of NSABP B-32, a randomised phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node negative breast cancer patients Breast Cancer Res Treat 88 Suppl 1 2004 S11
48. I. de Mascarel F. Bonichon J.M. Coindre M. Trojani Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow-up Br J Cancer 66 3 1992 523-527
49. S. Braun B.S. Cevlati C. Assemi W. Janni C.R. Kentenich C. Schindlbeck et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy J Clin Oncol 19 5 2001 1468-1475
50. C. Colpaert P. Vermeulen W. Jeuris P. van Beest G. Goovaerts J. Weyler et al. Early distant relapse in 'node-negative' breast cancer is not predicted by occult axillary lymph node metastases but by the features of the primary tumour J Pathol 193 4 2001 442-449
51. V.C. Tjan-Heijnen P. Buit L.M. de Widt-Evert T.J. Ruers L.V. Beex Micrometastases in axillary lymph nodes: An increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure Breast Cancer Res Treat 70 2 2001 81-88
52. K. Dowlatshahi M. Fan H.C. Snider F.A. Habib Lymph node micrometastases from breast carcinoma: Reviewing the dilemma Cancer 80 7 1997 1188-1197
53. M.M. Steinhoff Axillary node micrometastases: Detection and biologic significance Breast J 5 5 1999 325-329
54. R.J. Cote H.F. Peterson B. Chaiwun R.D. Gelber A. Goldhirsch M. Castiglione-Gertsch et al. Role of immunohistochemical detection of lymph node metastases in the management of breast cancer. International Breast Cancer Study Group Lancet 354 9182 1999 896-900
55. Y. Umekita Y. Ohi Y. Sagara H. Yoshida Clinical significance of occult micrometastases in axillary lymph nodes in 'node-negative' breast cancer patients Jpn J Cancer Res 93 6 2002 695-698
56. S. Giard M.C. Baranzelli D. Robert M.P. Chauvet Y.M. Robin V. Cabaret et al. Surgical implications of sentinel node with micrometastatic disease in invasive breast cancer Eur J Surg Oncol 30 9 2004 924-929
57. R. Holland J.L. Connolly R. Gelman M. Mravunac J.H. Hendriks A.L. Verbeek et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast J Clin Oncol 8 1990 113-118
58. M.J. Silverstein M.D. Lagios P.H. Craig J.R. Waisman B.S. Lewinsky W.J. Colburn et al. A prognostic index for ductal carcinoma in situ of the breast Cancer 77 1996 2267-2274
59. M.J. Silverstein M.D. Lagios S. Groshen J.R. Waisman B.S. Lewinsky S. Martino et al. The influence of margin width on local control of ductal carcinoma in situ of the breast N Engl J Med 340 1999 1455-1461
60. B. Fisher J. Dignam N. Wolmark E. Mamounas J. Costantino W. Poller et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from national surgical adjuvant breast and bowel project B-17 J Clin Oncol 16 1998 441-452
61. J.P. Julien N. Bijker I.S. Fentiman J.L. Peterse V. Delledonne P. Rouanet et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group Lancet 355 2000 528-533
62. H.M. Bishop R.W. Blamey A.H. Morris D.H. Rose B. Preston J. Lane et al. Bone scanning: Its lack of value in the follow up of patients with breast cancer Br J Surg 66 1979 752-754
63. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators JAMA 1994 271 1587-92
64. Oncology ASoC Recommended breast cancer surveillance guidelines J Clin Oncol 15 1997 2149-2156
65. B. Salvadori C. Bartoli S. Zurrida V. Delledonne P. Squicciarini D. Rovini et al. Risk of invasive cancer in women with lobular carcinoma in situ of the breast Eur J Cancer 27 1991 35-37
66. C.A. Bodian K.H. Perzin R. Lattes Lobular neoplasia. Long term risk of breast cancer and relation to other factors Cancer 78 1996 1024-1034
67. P.P. Rosen C. Kosloff P.H. Lieberman F. Adair D.W. Braun Jr Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years Am J Surg Pathol 2 1978 225-251
68. E.R. Fisher J. Costantino B. Fisher A.S. Palekar S.M. Paik C.M. Suarez et al. Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B-17. Five-year observations concerning lobular carcinoma in situ Cancer 78 1996 1403-1416
69. M. Overgaard P.S. Hansen J. Overgaard C. Rose M. Anderson F. Bach et al. Post-operative radiotherapy in high-risk pre menopausal breast cancer who receive adjuvant chemotherapy. Danish Breast Cooperative Group S2b Trial N Engl J Med 337 1997 949-955
70. M. Overgaard M.B. Jensen J. Overgaard et al. Post-operative radiotherapy in high-risk post menopausal breast cancer patients given adjuvant tamoxifen. Danish Breast Cooperative Group DBCG 82c randomised trial Lancet 353 1999 1641-1648
71. Cancer care and treatment services; advice for purchasers and providers. The Royal College of Radiologists; 1991
72. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998 351 1451-67
73. R. Blamey On behalf of the ZEBRA Trialists' Group The ZEBRA study: Zoladex is as effective as CMF in pre/perimenopausal patients with oestrogen receptor positive, node positive early breast cancer Eur J Cancer 37 Suppl 5 2001 39
74. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial Lancet 359 2002 2131-2139
75. A. Howell On behalf of the ATAC Trialists Group The ATAC trial in postmenopausal women with early breast cancer-updated efficacy results based on a median follow-up of 5 years Breast Cancer Res Treat 88 Suppl 1 2004 S7
76. P. Goss J. Ingle S. Martino N. Robert H. Muss M. Piccart et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793-1802
77. R.C. Coombes E. Hall L.J. Gibson R. Paridaens J. Jassem T. Delozier et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081-1092
78. Early Breast Cancer Trials Collaborative Group Polychemotherapy for early breast cancer: An overview of the randomised trials Lancet 352 1998 930-942
79. E. Joseph M. Hyacinthe G.H. Lyman C. Busch L. Demps D.S. Reintgen et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer Ann Surg Oncol 5 1998 522-528
80. T. Wheeler S. Stenning S. Negus S. Picken S. Metcalfe Evidence to support a change in follow-up policy for patients with breast cancer: Time to first relapse and hazard rate analysis Clin Oncol 11 1999 169-173
81. S. Ciatto Detection of breast cancer local recurrences Ann Oncol 6 Suppl 2 1995 23-26
82. M. Rosselli Del Turco D. Palli A. Cariddi S. Ciatto P. Pacini V. Distante Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up JAMA 271 1994 1593-1597
83. T. Gulliford M. Opomu E. Wilson I. Hanham R. Epstein Popularity of less frequent follow up for breast cancer in randomised study: Initial findings from the hotline study BMJ 314 1997 174-177
84. S.A. Harries R.L. Lawrence R. Scrivener N.R. Fieldman M.W. Kissin The investigation and treatment of breast cancer in England and Wales Ann R Coll Surg Engl 78 1996 197-202
85. The use of imaging in the follow-up of patients with breast cancer. London: The Royal College of Radiologists 1995
86. T.R. Rebbeck H.T. Lynch S.L. Neuhausen S.A. Narod L. Van't Veer J.E. Garber et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 2002 1616-1622
87. S.A. Narod J.S. Brunet P. Ghadirian M. Robson K. Heimdal S.L. Neuhausen et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group Lancet 356 2000 1876-1881
88. E.J. Meijers-Heijboer L.C. Verhoog C.T. Brekelmans C. Seynaeve M.M. Tilanus-Linthorst A. Wagner et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation Lancet 355 2000 2015-2020
89. Watson M Foster C Eeles R Eccles D Ashley S Davidson R et al. and the Psychosocial Study Collaborators. Psychological impact of breast/ovarian (BRCA1/2) cancer predictive gene testing in a UK multi-centre clinical cohort Br J Cancer 2004 91 1787-94
90. S.R. Lakhani M.J. Van der Vijver J. Jacquemier T.J. Anderson P.P. Osin L. McGuffog et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2 and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 2002 2310-2318
91. D. Eccles P. Simmonds J. Goddard M. Coultas S. Hodgson F. Lalloo et al. Familial breast cancer: An investigation into the outcome of treatment for early stage disease Fam Cancer 1 2001 65-72
92. D.G. Evans A. Howell Are BRCA1 and BRCA2 related breast cancers associated with increased mortality? Breast Cancer Res 6 2004 E7
93. T.E. Alpert B.G. Haffty Conservative management of breast cancer in BRCA1/2 mutation carriers Clin Breast Cancer 5 2004 37-42
94. M.D. Schwartz C. Lerman B. Brogan B.N. Peshkin C.H. Halbert T. DeMarco et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients J Clin Oncol 22 2004 1823-1829
95. H.M. Bebbington L.J. Fallowfield A qualitative study looking at the psychosocial implications of bilateral prophylactic mastectomy Breast 12 2003 1-9
96. B.N. Peshkin C. Isaacs C. Finch S. Kent M.D. Schwartz Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians J Clin Oncol 21 2003 4322-4328
97. M.E. Robson P.O. Chappuis J. Satagopan N. Wong J. Boyd J.R. Goffin et al. combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Breast Cancer Res 6 2004 R8-R17
98. B. Salvadori E. Marubini R. Miceli A.R. Conti F. Cusumano S. Andreola et al. Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery Br J Surg 86 1999 84-87
99. The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology, 1999. Eur J Surg Oncol 1999 25 3-23
100. A curriculum and organisation for higher surgical training in general surgery and its sub-specialities. The Royal College of Surgeons of England Joint Committee on Higher Surgical Training 1998
101. T. Bates R. Blamey The training of a surgeon with an interest in breast disease Eur J Surg Oncol 22 Suppl A 1996 2-4
102. C.A. Stiller Survival in patients with breast cancer: Those in clinical trials do better BMJ 299 1989 1056-1059